The seasoned approach
ECT in 2026 remains the most effective treatment in psychiatry for the right indications. The discipline is to use it where it is the right answer, deploy modern technique to minimize cognitive cost, and integrate it with broader treatment.
Layer 1 — The indications where ECT is first-line interventional
Severe melancholic depression with psychotic features, catatonia (medical emergency), severe suicidality with imminent risk, treatment-emergent mania requiring rapid control, severe depression with substantial weight loss or refusal to eat/drink, post-partum psychosis with severity. Patients in these categories benefit from ECT earlier than the standard "after multiple medication failures" pathway.
Layer 2 — The indications where ECT is interventional after TRD pathway
Moderate-to-severe TRD after adequate medication trials and augmentation. The choice between ECT and TMS in this category depends on severity, cognitive considerations, and patient preference. ECT has higher efficacy; TMS has better cognitive profile.
Layer 3 — Modern technique — ultrabrief pulse, right unilateral first
Ultrabrief pulse (0.3ms) instead of brief pulse (0.5–1ms) — comparable efficacy with substantially reduced cognitive impact. Right unilateral first-line — comparable efficacy to bilateral for most patients with less cognitive impact. Bitemporal reserved for cases where unilateral is inadequate. Individualized stimulus titration during initial session.
Layer 4 — Acute course and continuation
Acute course typically 6–12 treatments over 2–4 weeks (3 treatments weekly). Continuation ECT after acute course — weekly to monthly for 6 months — substantially reduces relapse risk. Maintenance ECT in patients with recurrent severe presentation may extend much longer. The continuation phase is underused; many patients receive acute course only and relapse.
Layer 5 — Cognitive monitoring
Baseline cognitive assessment (MMSE, MoCA, or more detailed). Periodic assessment during treatment. Persistent cognitive concerns warrant attention — adjust laterality, stimulus parameters, treatment frequency. Most cognitive effects resolve within weeks to months of treatment completion; persistent significant memory effects are possible particularly with bilateral protocols.
Layer 6 — Integration with medication and psychotherapy
Most antidepressants and mood stabilizers are continued through ECT (with attention to specific interactions — lithium and benzodiazepines may interfere with seizure threshold). Psychotherapy continues. Post-ECT plan addresses maintenance medication, continuation ECT if indicated, ongoing psychotherapy, behavioral foundation.
Special situations
- Catatonia: Often a medical emergency; ECT may be needed urgently. Lorazepam trial first (1–2mg, may need higher); if inadequate response, ECT — sometimes within 24–48 hours. Catatonia carries substantial morbidity and mortality if not treated promptly; the urgency justifies expedited ECT consideration.
- Severe depression with active suicidality and refusal to eat: ECT consideration within days of presentation, not after weeks of medication trial failure. The mortality risk of severe melancholic depression with nutritional refusal justifies expedited intervention.
- Older adult with TRD and cognitive complaints: ECT carries cognitive cost particularly in this population. TMS first-line if depression severity allows. ECT remains an option if TMS inadequate, but the cognitive trade-offs are substantial — discuss honestly with patient and family. Right unilateral, ultrabrief pulse, individualized titration to minimize cognitive impact.
- Pregnancy with severe depression: ECT is one of the few treatments with adequate safety data in pregnancy and is sometimes the right answer for severe maternal depression. Coordination with obstetrics for fetal monitoring during treatment.
Generally avoid
- Delaying ECT in severe presentations — melancholic depression with psychotic features, catatonia, severe suicidality with refusal to eat all warrant expedited ECT consideration rather than prolonged medication trials.
- Discontinuing ECT immediately after acute response without continuation — relapse rates are high without continuation ECT or aggressive maintenance pharmacotherapy.
- Bilateral ECT as default when right unilateral is adequate — the cognitive cost difference is meaningful and most patients respond to RUL.
- Cancelling ECT consultation due to general cognitive concerns without weighing severity — patients with severe presentations may have substantially worse outcomes from prolonged untreated depression than from ECT cognitive cost.
The chief-resident note: ECT remains the most effective treatment in psychiatry. The history of overuse and harm has produced an underuse swing in some clinical cultures, with patients suffering severe presentations because clinicians and systems are reluctant to consider ECT. The modern technique substantially reduces cognitive cost; the indications where ECT is first-line are real; the patients who benefit most are often the most vulnerable. Build the practice to engage ECT seriously when it is the right answer — early referral, coordinated post-acute care, continuation ECT when indicated. The cost of an unnecessary ECT course is real; the cost of a delayed ECT course in someone who needs it is sometimes their life.
Electroconvulsive therapy in 2026 remains the most effective treatment in psychiatry for the right indications. The modern technique — ultrabrief pulse, right unilateral first-line, individualized stimulus titration, sophisticated anesthesia and monitoring infrastructure — has substantially reduced the cognitive cost compared to historical protocols, while preserving the efficacy that distinguishes ECT from other treatments. The clinical discipline is to use ECT where it is the right answer, deploy modern technique to minimize cognitive cost, and integrate it with broader treatment for durable outcomes.
The indications where ECT remains first-line interventional treatment are substantive. Severe melancholic depression with psychotic features responds to ECT more reliably than to medication alone, often dramatically within a few treatments. Catatonia is frequently a medical emergency requiring ECT if benzodiazepine trial is inadequate. Severe suicidality with imminent risk warrants ECT consideration earlier than the standard "after multiple medication failures" pathway. Treatment-emergent mania requiring rapid control, severe depression with weight loss or refusal to eat or drink, and post-partum psychosis with severity are scenarios where ECT may be the appropriate early intervention. Patients in these categories benefit from being offered ECT consultation as part of initial severe-presentation management, not as a last resort after months of medication failure.
Modern technique substantially differs from historical protocols. Ultrabrief pulse (0.3ms instead of 0.5–1.0ms) produces comparable efficacy with substantially reduced cognitive impact. Right unilateral electrode placement is now first-line in most modern programs — comparable efficacy to bilateral for the majority of patients with significantly less cognitive impact, particularly for memory effects. Bitemporal placement is reserved for cases where unilateral is inadequate or where rapid response is critical. Individualized stimulus titration during the initial session calibrates dose to seizure threshold rather than using fixed parameters. These technique advances have transformed the cognitive risk-benefit calculation.
The continuation phase is underused. Acute ECT course (6–12 treatments over 2–4 weeks) produces high response rates but relapse rates are substantial without ongoing treatment. Continuation ECT — weekly to monthly treatments for 6 months — substantially reduces relapse, with growing evidence supporting this practice. Maintenance ECT in patients with recurrent severe presentation may extend much longer, sometimes for years. The "course of ECT" should typically be conceived as acute + continuation + (sometimes) maintenance, not just acute treatment with hope that medication will sustain response.
Cognitive monitoring and adjustment is part of modern ECT practice. Baseline cognitive assessment (MMSE, MoCA, sometimes more detailed neuropsychological testing) provides comparison for periodic reassessment during treatment. Persistent cognitive concerns warrant adjustment — laterality (move from bilateral to unilateral if not already), pulse width (move to ultrabrief if not already), session frequency (every 72 hours rather than every other day), stimulus dose. Most cognitive effects resolve within weeks to months of treatment completion; persistent significant memory effects are possible, particularly with bilateral protocols, and the conversation with patients and families includes this honestly.
The integration with medication, psychotherapy, and broader care is essential for durable outcomes. Most antidepressants and mood stabilizers are continued through ECT (with attention to specific interactions — lithium and benzodiazepines may interfere with seizure threshold). Psychotherapy continues alongside ECT and is particularly important during the integration phase. Behavioral foundation — sleep, exercise, social engagement, dietary attention — is part of the longevity-psychiatry frame even during interventional treatment. The post-ECT plan addresses maintenance medication, continuation ECT if indicated, ongoing psychotherapy, and the broader cognitive-optimization prescription. The discipline is to engage ECT seriously when it is the right answer, deploy modern technique to minimize the cognitive cost, and integrate it with broader treatment for durable outcomes — the patient who benefits from ECT deserves the full clinical infrastructure that makes the treatment effective and tolerable.